Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 89, Issue 5, 2010, Pages 351-363

  Martin, Pauline L ^a   Sachs, Clifford ^a   Imai, Noritaka ^b   Tsusaki, Hideshi ^b   Oneda, Satoru ^c   Jiao, Qun ^a   Treacy, George ^a  

^a CENTOCOR INC   (United States)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

^c SNBL USA Ltd   (United States)

Author keywords

Cynomolgus macaque; Embryogenesis; Interleukin 12; Interleukin 23; Postnatal evaluation; Safety assessment; Ustekinumab

Indexed keywords

USTEKINUMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BREAST MILK; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; EMBRYO DEVELOPMENT; FEMALE; FETUS; FETUS DEVELOPMENT; GESTATIONAL AGE; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; LACTATION; LYMPHOID TISSUE; MACACA; MALE; MATERNAL SERUM; NONHUMAN; ORGANOGENESIS; PERIPHERAL LYMPHOCYTE; POSTNATAL DEVELOPMENT; PREGNANCY; PRENATAL DEVELOPMENT; PRIORITY JOURNAL; T LYMPHOCYTE; TERATOGENICITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; EMBRYONIC DEVELOPMENT; FEMALE; FETUS; HUMANS; IMMUNE SYSTEM; INFANT; LACTATION; MACACA FASCICULARIS; PREGNANCY;

MACACA;

EID: 78650498507     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.20250     Document Type: Article

References (44)

1. Barrie AM, Plevy SE. 2005. The interleukin-12 family of cytokines: therapeutic targets for inflammatory disease mediation. Immunol Rev 5:225-240.
2. Brok HPM, van Meurs M, Blezer E, Schantz A, Peritt D, Treacy G, Laman JD, Bauer J, Hart BA. 2002. Prevention of experimental autoimmune encephalomyelitis in common marmosets using and anti-IL-12p40 monoclonal antibody. J Immunol 169:6554-6563.
3. Buchtova M, Tichy F, Putnova I, Misek I. 2003. The development of palatal rugae in the European pine vole, Microtus subterraneus (Arvicolidae, Rodentia). Folia Zool 52:127-136.
4. Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I, Katz S, Krone CL, Vander Vliet M, Stevens C, Sherman ML, Jacobson E, Bleday R. 2006. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 12:558-565.
5. Chellman GJ, Bussiere JL, Makori N, Martin PL, Ooshima Y, Weinbauer GH. 2009. Developmental and reproductive toxicology studies in nonhuman primates. Birth Def Res B 86:446-462.
6. Coe CL, Kemnitz JW, Schneider ML. 1993. Vulnerability of placental antibody transfer and fetal complement synthesis to disturbance of the pregnant monkey. J Med Primatol 22:294-300.
7. Dawson AB. 1926. A note on the staining of skeleton of cleared specimens with alizarin red S. Stain Technol 1:123-125.
8. Ding C, Xu J, Li J. 2008. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Curr Opin Invest Drugs 9:515-522.
9. Elliott M, Benson J, Blank M, Brodmerkel C, Baker D, Ruley Sharples K, Szapary P. 2009. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann NY Acad Sci 1182:97-110.
10. Fujimoto K, Terao K, Cho F, Honjo S. 1983. The placental transfer of IgG in the cynomolgus monkey. Jpn J Med Sci Biol 36:171-176.
11. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. 2009. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373:633-640.
12. Hart BA, Brok HPM, Remarque E, Benson J, Treacy G, Amor S, Hintzen RQ, Laman JD, Bauer J, Blezer ELA. 2005. Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human anti-human IL-12p40 antibody. J Immunol 175:4761-4768.
13. Hauser G, Daponte A, Roberts J. 1989. Palatal rugae. J Anat 165:237-249.
14. Hendrickx AG, Korte R, Leuschner F, Neumann BW, Poggel A, Binkerd P, Prahalada S, Günzel P. 1987. Embryotoxicity of sex steroidal hormone combinations in nonhuman primates: I. Norethisterone acetate+ethinylestradiol and progesterone+estradiol benzoate (Macaca mulatta, Macaca fascicularis, and Papio cynocepalus). Teratology 35:119-127.
15. Hendrie TA, Peterson PE, Short JJ, Tarantal AF, Rothgarn E, Hendrie MI, Hendrickx AG. 1996. Frequency of prenatal loss in a macaque breeding colony. Am J Primatol 40:41-53.
16. Herzyk DJ, Soos JM, Maier CC, Gore ER, Narayanan PK, Nadwodny KL, Lui S, Jonak ZL, Bugelski PJ. 2002. Immunopharmacology of recombinant human interleukin-18 in nonhuman primates. Cytokine 20:38-48.
17. Ichikawa M, Koh CS, Inoue A, Tsyusaki J, Yamazski M, Inaba Y, Sekiguchi Y, Itoh M, Yagita H, Komiyama A. 2000. Anti-IL-12 antibody presents the development and progression of multiple sclerosis-like relapsing-remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide. J Neuroimmunol 102:56-66.
18. Ikemi N, Otanic Y, Ikegamic T, Yasuda M. 2001. Palatal ruga anamoly induced by all-trans-retinoic acid in the Crj: SD rat: possible warning sign of teratogenicity. Reprod Toxicol 15:87-93.
19. Kane S, Ford J, Cohen R, Wagner C. 2009. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 43:613-616.
20. Lima XT, Abuabara K, Kimball AB, Lima HC. 2009. Briakinumab. Expert Opin Biol Ther 9:1107-1113.
21. Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY, Ferrante J, Stewart C, Sarmiento U, Faherty DA, Gately MK. 1996. IL-12 deficient mice are defective in ILNγ production and type 1 cytokine responses. Immunity 4:471-481.
22. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. 1996. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 36:248-255.
23. Martin PL. 2008. Reproductive toxicity testing for biopharmaceuticals. In: Cavagnaro J, editor. Preclinical safety evaluation of biopharmaceuticals: a science-based approach to facilitating clinical trials. Hoboken: John Wiley & Sons. p 357-378.
24. Martin PL, Buse E. 2008. Developmental immunotoxicity in nonhuman primates. In: Herzyk DJ, Bussiere JL, editors. Immunotoxicology strategies for pharmaceutical safety assessment. Hoboken: John Wiley and Sons. p 299-318.
25. Martin PL, Oneda S, Treacy G. 2007. Effects of an anti-TNFα monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol 58:138-149.
26. Martin PL, Breslin W, Rocca M, Wright D, Cavagnaro J. 2009. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals. Birth Defects Res B 86:176-203.
27. Nayak P, Achary AB, Padmini AT, Kaveri H. 2007. Differences in the palatal rugae shape in two populations of India. Arch Oral Biol 52:977-982.
28. Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W. 1995. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182:1281-1290.
29. Palfi M, Selbring A. 1998. Placental transport of maternal immunoglobulin G. Am J Reprod Immunol 39:24-26.
30. Pentšuk N, van der Laan JW. 2009. An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B 86:328-344.
31. Reddy M, Davis Cue, Wong J, Marsters P, Pendley C, Prabhakar U. 2007. Modulation of CLA, IL12R, CD40L, and IL-2Rα expression and inhibition of Il-12 and Il-23-induced cytokine secretion by CNTO 1275. Cell Immunol 247:1-11.
32. Scanlon JV. 2009. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis. Annal Pharmacother 43:1456-1465.
33. Simister NE. 2003. Placental transport of immunoglobulin G. Vaccine 21:3365-3369.
34. Stengel JZ, Arnold HL. 2008. Is infliximab safe to use while breastfeeding? World J Gastroenterol 14:3085-3087.
35. Stewart J. 2009. Reproductive toxicology developmental toxicity testing of monoclonal antibodies: an enhanced pre- and postnatal study design option. Reprod Toxicol 28:220-225.
36. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. 2006. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 4:1255-1258.
37. Veldman GM. 2006.Targeting the p40 cytokines interleukin (IL)-12 and IL-23 in Crohn's disease. Drug Discov Today 3:375-380.
38. Weber J, Keam SJ. 2009. Ustekinumab. BioDrugs 23:53-61.
39. Wehner NG, Shopp G, Oneda S, Clarke J. 2009. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor. Birth Def Res B 86:117-130.
40. Weinbauer GF, Niehoff M, Niehaus M, Srivastav S, Fuchs A, Van Esch E, Cline JM. 2008. Physiology and endocrinology of the ovarian cycle in macaques. Toxicol Pathol 36:7S-23S.
41. Weinbauer GF, Frings W, Fuchs ANM, Osterburg I. 2008. Reproductive/developmental toxicity assessment of biopharmaceuticals in nonhuman primates. In: Cavagnaro JA, editor. Preclinical safety evaluation of biopharmaceuticals. A science-based approach to facilitating clinical trials. Hoboken, NJ: John Wiley & Sons, Inc. p 379-397.
42. Werner M, Chott A, Fabiano A, Battifora Hector 2000. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 24:1016-1019.
43. Yasuda M, Horie S, Matsui K, Takagi T, Yamashita K. 1998. Variant patterns of palatal rugae induced by chemicals in mouse fetuses. Cong Anom 38:87-95.
44. Yasuda M, Sumida H, Arima A, and Kubota S. 2007. Palatal rugae in adult rhesus monkeys. Cong Anom 47:A30.